Title: A Multicenter, Open-label, Phase 1b/2 Study To Evaluate Safety And Efficacy Of Avelumab (msb0010718c) In Combination With Chemotherapy With Or Without Other Anti-cancer Immunotherapies As First-line Treatment In Patients With Advanced Malignancies1

Principal Investigators: None listed.

Description: For this open-label, non-randomized phase 1b/2 trial (ClinicalTrials.gov Identifier: NCT03317496), researchers are evaluating whether avelumab, a PD-L1 inhibitor, is safe and effective in combination with chemotherapy for treating patients with non–small cell lung cancer (NSCLC) or urothelial cancer.

Continue Reading

Patients with NSCLC (cohort A1) will receive pemetrexed, carboplatin, and avelumab; all participants will have advanced non-squamous disease. Patients with urothelial cancer (cohort A2) will receive gemcitabine, cisplatin, and avelumab.

The primary outcomes of the phase 1b part are the number of patients with dose-limiting toxicities and the confirmed objective response rate. Secondary outcomes include progression-free survival, duration of response, and overall survival.

The estimated enrollment is 80 patients.

For more study information, including inclusion and exclusion criteria, study locations, and contact information, visit https://clinicaltrials.gov/ct2/show/NCT03317496.

This study is sponsored by Pfizer.


  1. Clinicaltrials.gov. Safety and efficacy study of avelumab plus chemotherapy with or without other anti-cancer immunotherapy agents in patients with advanced malignancies.  NCT03317496. https://clinicaltrials.gov/ct2/show/NCT03317496. Accessed January 26, 2018.